No FDA-approved hantavirus vaccine is expected by December 2026, as reflected in the 94.5% market-implied probability for “No.” No orthohantavirus candidates have advanced beyond early Phase 1 or preclinical stages, with DNA and mRNA platforms targeting Gn-Gc glycoproteins showing only neutralizing antibody responses in limited human or animal testing. Low disease incidence, rodent-borne transmission, and the absence of Phase 3 efficacy trials for HPS or HFRS make timely licensure improbable under standard regulatory pathways. Recent 2026 outbreaks have prompted modest surveillance and funding increases from agencies like the CDC and WHO, yet these developments do not compress multi-year timelines. Accelerated approval or emergency use authorization remains theoretically possible but lacks precedent for this pathogen.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้วHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% โอกาส
$129,605 ปริมาณ
$129,605 ปริมาณ
Dec 31, 2026
6% โอกาส
$129,605 ปริมาณ
$129,605 ปริมาณ
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No FDA-approved hantavirus vaccine is expected by December 2026, as reflected in the 94.5% market-implied probability for “No.” No orthohantavirus candidates have advanced beyond early Phase 1 or preclinical stages, with DNA and mRNA platforms targeting Gn-Gc glycoproteins showing only neutralizing antibody responses in limited human or animal testing. Low disease incidence, rodent-borne transmission, and the absence of Phase 3 efficacy trials for HPS or HFRS make timely licensure improbable under standard regulatory pathways. Recent 2026 outbreaks have prompted modest surveillance and funding increases from agencies like the CDC and WHO, yet these developments do not compress multi-year timelines. Accelerated approval or emergency use authorization remains theoretically possible but lacks precedent for this pathogen.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
ตลาดเปิดเมื่อ: May 4, 2026, 10:39 AM ET
ปริมาณการซื้อขาย
$129,605วันสิ้นสุด
Dec 31, 2026ตลาดเปิดเมื่อ
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.No FDA-approved hantavirus vaccine is expected by December 2026, as reflected in the 94.5% market-implied probability for “No.” No orthohantavirus candidates have advanced beyond early Phase 1 or preclinical stages, with DNA and mRNA platforms targeting Gn-Gc glycoproteins showing only neutralizing antibody responses in limited human or animal testing. Low disease incidence, rodent-borne transmission, and the absence of Phase 3 efficacy trials for HPS or HFRS make timely licensure improbable under standard regulatory pathways. Recent 2026 outbreaks have prompted modest surveillance and funding increases from agencies like the CDC and WHO, yet these developments do not compress multi-year timelines. Accelerated approval or emergency use authorization remains theoretically possible but lacks precedent for this pathogen.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
ปริมาณการซื้อขาย
$129,605วันสิ้นสุด
Dec 31, 2026ตลาดเปิดเมื่อ
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...No FDA-approved hantavirus vaccine is expected by December 2026, as reflected in the 94.5% market-implied probability for “No.” No orthohantavirus candidates have advanced beyond early Phase 1 or preclinical stages, with DNA and mRNA platforms targeting Gn-Gc glycoproteins showing only neutralizing antibody responses in limited human or animal testing. Low disease incidence, rodent-borne transmission, and the absence of Phase 3 efficacy trials for HPS or HFRS make timely licensure improbable under standard regulatory pathways. Recent 2026 outbreaks have prompted modest surveillance and funding increases from agencies like the CDC and WHO, yet these developments do not compress multi-year timelines. Accelerated approval or emergency use authorization remains theoretically possible but lacks precedent for this pathogen.
สรุปจาก AI ทดลองที่อ้างอิงข้อมูลจาก Polymarket ไม่ใช่คำแนะนำในการเทรดและไม่มีผลต่อการตัดสินตลาดนี้ · อัปเดตแล้ว
ระวังลิงก์ภายนอก
ระวังลิงก์ภายนอก
คำถามที่พบบ่อย